Ignite Creation Date:
2025-12-25 @ 2:36 AM
Ignite Modification Date:
2026-06-20 @ 1:03 PM
Study NCT ID:
NCT02497534
Status:
RECRUITING
Last Update Posted:
2025-09-23
First Post:
2015-07-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Biomarkers in Friedreich's Ataxia
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D005621', 'term': 'Friedreich Ataxia'}, {'id': 'D001259', 'term': 'Ataxia'}], 'ancestors': [{'id': 'D013132', 'term': 'Spinocerebellar Degenerations'}, {'id': 'D002526', 'term': 'Cerebellar Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D020271', 'term': 'Heredodegenerative Disorders, Nervous System'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D028361', 'term': 'Mitochondrial Diseases'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D020820', 'term': 'Dyskinesias'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'CASE_CONTROL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 203}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2015-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-09', 'completionDateStruct': {'date': '2030-06-03', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-09-17', 'studyFirstSubmitDate': '2015-07-07', 'studyFirstSubmitQcDate': '2015-07-09', 'lastUpdatePostDateStruct': {'date': '2025-09-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2015-07-14', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2030-06-03', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Cardiac MRI', 'timeFrame': 'Baseline and Follow-Up Visits', 'description': 'Cardiac MRI will be used to characterize cardiac morphology and function.'}, {'measure': 'Echocardiogram', 'timeFrame': 'Baseline and Follow-Up Visits', 'description': 'Echocardiogram will be used to characterize cardiac morphology and function.'}, {'measure': "Friedreich's Ataxia Rating Scale (FARS)", 'timeFrame': 'Baseline and Follow-Up Visits', 'description': 'FARS scores describe specific neurological impairments in FA.'}, {'measure': 'Metabolic exercise testing', 'timeFrame': 'Baseline and Follow-Up Visits', 'description': 'Metabolic exercise testing will be performed on either a recumbent bike or hand ergometer and will measure the maximal amount of exercise the subject is able to perform.'}, {'measure': 'Scale for the Assessment and Rating of Ataxia (SARA)', 'timeFrame': 'Baseline and Follow-Up Visits', 'description': 'Clinical scale assessing impairment levels in cerebellar ataxia'}, {'measure': 'Muscle Biopsy', 'timeFrame': 'Baseline', 'description': 'The muscle sample will be used to evaluate Frataxin quantification'}, {'measure': 'Skin Biopsy', 'timeFrame': 'Baseline', 'description': "Analyses to peripheral tissue used to find out how Friedreich's Ataxia develops."}, {'measure': '9-Hole-Peg Test', 'timeFrame': 'Baseline and Follow-Up Visits', 'description': 'Assesses upper extremity function and motor coordination.'}, {'measure': 'Pulmonary Function Testing', 'timeFrame': 'Baseline and Follow-Up Visits', 'description': 'Breathing tests to assess lung strength and function.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['ataxia', 'neuromuscular'], 'conditions': ["Friedreich's Ataxia"]}, 'descriptionModule': {'briefSummary': 'The purpose of this project is to characterize measures of cardiac performance and neuromuscular physiology in FA patients using novel techniques, including echocardiography and magnetic resonance imaging (MRI), metabolic exercise testing, and neurophysiological outcomes.', 'detailedDescription': "Friedreich's ataxia (FA) is an autosomal recessive disease caused by a mutation in the frataxin gene (FXN). Although rare, FA is the most common form of hereditary ataxia, affecting 1 in every 50,000 people in the United States. Currently, palliative therapies are the only treatment for FA patients. However, current gene therapy efforts in other neuromuscular diseases have positioned the investigator's research program to extend these discoveries and techniques to FA. As new therapies become available for clinical application, it is crucial to identify non-invasive outcomes measures of cardiac and neuromuscular performance with adequate sensitivity to detect the impact of treatments."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '6 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': "Subjects with Friedreich's ataxia, healthy control subjects, and carriers of Friedreich's ataxia", 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Genetic diagnosis of Friedreich's ataxia by DNA sequencing, mutational analysis or protein assay OR be a healthy subject with no evidence of a neuromuscular disorder\n* Between the ages of 6 and 70 (inclusive)\n* Are able to tolerate metabolic exercise testing\n* Are stable on cardiac medication regimen for 3 months prior to screening\n\nExclusion Criteria:\n\n* Presence of unstable heart disease\n* Receipt of cardiac transplant\n* Any concurrent medical condition which, in the opinion of the investigators, would make the subject unsuitable for the study"}, 'identificationModule': {'nctId': 'NCT02497534', 'briefTitle': "Biomarkers in Friedreich's Ataxia", 'organization': {'class': 'OTHER', 'fullName': 'University of Florida'}, 'officialTitle': "Biomarkers in Friedreich's Ataxia", 'orgStudyIdInfo': {'id': 'IRB201500369-N'}, 'secondaryIdInfos': [{'id': 'UL1TR000064', 'link': 'https://reporter.nih.gov/quickSearch/UL1TR000064', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'label': "Affected with Friedreich's ataxia", 'description': "Friedreich's ataxia patients aged 6 to 70 (inclusive). Assessments will include collection of genetic mutation reports, cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing with a recombinant bike and/or hand ergometer, pulmonary function testing, and gait analysis. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy."}, {'label': 'Healthy controls', 'description': "Health controls aged 6 to 70 (inclusive). Assessments will include cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing, hand ergometer for exercise testing, pulmonary function testing, gait analysis, and optional blood draws and/or muscle/skin biopsies"}, {'label': "Carriers of Friedreich's ataxia", 'description': "An obligate carrier aged 18 to 70 (inclusive) of the abnormal Friedreich's ataxia gene by being a parent of a child with Friedreich's ataxia. No assessments are to be conducted. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy."}]}, 'contactsLocationsModule': {'locations': [{'zip': '32610', 'city': 'Gainesville', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Mackenzi Coker, MS, CCC-SLP', 'role': 'CONTACT', 'email': 'mcoker@ufl.edu', 'phone': '352-294-8754'}, {'name': 'Manuela Corti, PT, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Sub Subramony, MD', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'University of Florida', 'geoPoint': {'lat': 29.65163, 'lon': -82.32483}}], 'centralContacts': [{'name': 'Mackenzi Coker, M.S.CCC-SLP', 'role': 'CONTACT', 'email': 'mcoker@peds.ufl.edu', 'phone': '352-294-8754'}], 'overallOfficials': [{'name': 'Manuela Corti, PT, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Florida'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Florida', 'class': 'OTHER'}, 'collaborators': [{'name': "Children's Miracle Network", 'class': 'OTHER'}, {'name': 'National Institutes of Health (NIH)', 'class': 'NIH'}, {'name': 'National Center for Advancing Translational Sciences (NCATS)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}